Lastly, it has been reported that α2β1 integrin and collagen I participate to doxorubicin-induced drug resistance in leukemia by either protecting leukemia cells from apoptosis through MAPK/ERK pathway activation (317), or by decreasing the DNA damage through the inhibition of Rac1 activation (318). The gene discussed is RAC1; the disease is leukemia.